Rationale for statins in the chemoprevention of prostate cancer

Current Urology Reports

Volumn 9, Issue 3, 2008, Pages 189-196

  Hamilton, Robert J ^b   Freedland, Stephen J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; FINASTERIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PLACEBO; SILDENAFIL; SIMVASTATIN;

ADVANCED CANCER; ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BRACHYTHERAPY; CANCER PATIENT; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CATALYSIS; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONFIDENCE INTERVAL; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ERECTILE DYSFUNCTION; FOLLOW UP; GENE ACTIVITY; GENE EXPRESSION; HEALTH SURVEY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; INCIDENCE; LIPID RAFT; LIPOGENESIS; LIVER DYSFUNCTION; LONG TERM CARE; MIGRATION INHIBITION; MITOSIS INHIBITION; MORTALITY; MULTIVARIATE ANALYSIS; MYALGIA; MYOPATHY; MYOSITIS; OVERALL SURVIVAL; PENIS ERECTION; PROSTATE CANCER; PROTEIN EXPRESSION; QUALITY OF LIFE; REVIEW; RHABDOMYOLYSIS; RISK FACTOR; SIDE EFFECT; SIGNAL TRANSDUCTION; STATISTICAL SIGNIFICANCE; TUMOR CELL; TUMOR GROWTH;

HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; PROSTATIC NEOPLASMS;

EID: 44449163871     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-008-0034-z     Document Type: Review

References (65)

1. Lamb E: Top 200 Prescription Drugs of 2006. Pharmacy Times, May 2007. Accessible at http://www.pharmacytimes.com/article.cfm?ID=4629. Accessed December 2007.
2. Baigent C, Keech A, Kearney PM, et al.: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267-1278.
3. Poynter JN, Gruber SB, Higgins PD, et al.: Statins and the risk of colorectal cancer. N Engl J Med 2005, 352:2184-2192.
4. Friis S, Poulsen AH, Johnsen SP, et al.: Cancer risk among statin users: a population-based cohort study. Int J Cancer 2005, 114:643-647.
5. Shannon J, Tewoderos S, Garzotto M, et al.: Statins and prostate cancer risk: a case-control study. Am J Epidemiol 2005, 162:318-325. The first paper to observe a significant inverse association between statin use and overall prostate cancer risk. This paper was also the first to suggest statins may preferentially inhibit or prevent aggressive prostate cancer.
6. Graaf MR, Beiderbeck AB, Egberts AC, et al.: The risk of cancer in users of statins. J Clin Oncol 2004, 22:2388-2394.
7. Platz EA, Leitzmann MF, Visvanathan K, et al.: Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst 2006, 98:1819-1825. This important publication was the first to solidify the association between statin use and advanced prostate cancer while demonstrating no association between statin use and overall prostate cancer. These researchers also elegantly controlled for use of PSA screening, as this is a potential source of bias and a common criticism of the studies pertaining to advanced prostate cancer.
8. Jacobs EJ, Rodriguez C, Bain EB, et al.: Cholesterol-lowering drugs and advanced prostate cancer incidence in a large US cohort. Cancer Epidemiol Biomarkers Prev 2007, 16:2213-2217. This paper furthered the work of Platz et al. [7••], observing an association between statin use and advanced prostate cancer, but not observing an association with overall prostate cancer.
9. Flick ED, Habel LA, Chan KA, et al.: Statin use and risk of prostate cancer in the California Men's Health Study Cohort. Cancer Epidemiol Biomarkers Prev 2007, 16:2218-2225. This paper also observed an association between statin use and advanced prostate cancer, observing no association with overall prostate cancer.
10. Murtola T, Tammela TLJ, Lahtela J, Auvinen A: Cholesterol-lowering drugs and prostate cancer risk: a population-based case-control study. Cancer Epidemiol Biomarkers Prev 2007, 16:2226-2232. This paper similarly observed an association between statin use and advanced prostate cancer. In particular, given the less prevalent use of PSA screening in the Finnish population, the potential bias introduced by statin users being more likely to participate in screening than non-users was minimized.
11. Murtola TJ, Tammela TLJ, Maattanen L, Auvinen A: Statins and prostate cancer among men participating in the Finnish Prostate Cancer Screening Trial [abstract 1719]. Proceedings of the American Urological Association Meeting. Anaheim, CA; May 19-24, 2007.
12. Dale KM, Coleman CI, Henyan NN, et al.: Statins and cancer risk: a meta-analysis. JAMA 2006, 295:74-80. Although not the first published, this paper was the most comprehensive, most rigorous, and received the most press of the three meta-analyses that conducted secondary analyses of the randomized controlled trials of statin use in the prevention of cardiovascular disease. This study found no association between statin use and overall prostate cancer risk.
13. Browning DR, Martin RM: Statins and risk of cancer: a systematic review and metaanalysis. Int J Cancer 2007, 120:833-843. This paper was a unique meta-analysis, contrasting pooled observational study results with secondary analyses of randomized controlled trials of statins in the prevention of cardiovascular disease. This study also observed that statin use was not associated with overall prostate cancer risk.
14. Goldstein JL, Brown MS: Regulation of the mevalonate pathway. Nature 1990, 343:425-430.
15. Rosenson RS: Current overview of statin-induced myopathy. Am J Med 2004, 116:408-416.
16. Kashani A, Phillips CO, Foody JM, et al.: Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation 2006, 114:2788-2797.
17. Siegel D, Lopez J, Meier J: Use of cholesterol-lowering medications in the United States from 1991 to 1997. Am J Med 2000, 108:496-499.
18. LaRosa JC: Pleiotropic effects of statins and their clinical significance. Am J Cardiol 2001, 88:291-293.
19. Thompson IM, Goodman PJ, Tangen CM et al.: The influence of finasteride on the development of prostate cancer. N Engl J Med 2003, 349:215-224.
20. Blais L, Desgagne A, LeLorier J: 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. Arch Intern Med 2000, 160:2363-2368.
21. Coogan PF, Rosenberg L, Strom BL: Statin use and the risk of 10 cancers. Epidemiology 2007, 18:213-219.
22. Kaye JA, Jick H: Statin use and cancer risk in the General Practice Research Database. Br J Cancer 2004, 90:635-637.
23. Cyrus-David MS, Weinberg A, Thompson T, Kadmon D: The effect of statins on serum prostate specific antigen levels in a cohort of airline pilots: a preliminary report. J Urol 2005, 173:1923-1925. The first paper to describe an association between statin use and lower PSA levels. Though a small study (n =15), we have recently confirmed this association in our larger, longitudinal study.
24. Hamilton RJ, Goldberg KC, Platz EA, Freedland SJ: The influence of statin medications on prostate specific antigen levels in healthy men [abstract 463]. Proceedings of the American Urological Association Annual Meeting. Anaheim, CA; May 19-24, 2007. Accessible at http://www. abstracts2view.com/aua/index.php.
25. Ciatto S, Zappa M, Villers A, et al.: Contamination by opportunistic screening in the European Randomized Study of Prostate Cancer Screening. BJU Int 2003, 92(Suppl 2):97-100.
26. Youssef S, Stuve O, Patarroyo JC, et al.: The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002, 420:78-84.
27. Weis M, Heeschen C, Glassford AJ, Cooke JP: Statins have biphasic effects on angiogenesis. Circulation 2002, 105:739-745.
28. Rao S, Porter DC, Chen X, et al.: Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. Proc Natl Acad Sci U S A 1999, 96:7797-7802.
29. Nubel T, Dippold W, Kleinert H, et al.: Lovastatin inhibits Rho-regulated expression of E-selectin by TNFalpha and attenuates tumor cell adhesion. Faseb J 2004, 18:140-142.
30. Kusama T, Mukai M, Iwasaki T, et al.: Inhibition of epidermal growth factor-induced RhoA translocation and invasion of human pancreatic cancer cells by 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors. Cancer Res 2001, 61:4885-4891.
31. Marcelli M, Cunningham GR, Haidacher SJ, et al.: Caspase-7 is activated during lovastatin-induced apoptosis of the prostate cancer cell line LNCaP. Cancer Res 1998, 58:76-83.
32. Wong WW, Tan MM, Xia Z, et al.: Cerivastatin triggers tumor-specific apoptosis with higher efficacy than lovastatin. Clin Cancer Res 2001, 7:2067-2075.
33. Demierre MF, Higgins PD, Gruber SB, et al.: Statins and cancer prevention. Nat Rev Cancer 2005, 5:930-942. A thorough review that provides the reader with more in-depth analysis of the antineoplastic mechanisms of statins than the scope of the current review allows.
34. Schaffner CP: Prostatic cholesterol metabolism: regulation and alteration. Prog Clin Biol Res 1981, 75A:279-324.
35. Nelson PS, Clegg N, Arnold H, et al.: The program of androgen-responsive genes in neoplastic prostate epithelium. Proc Natl Acad Sci U S A 2002, 99:11890-11895.
36. Swinnen JV, Van Veldhoven PP, Esquenet M, et al.: Androgens markedly stimulate the accumulation of neutral lipids in the human prostatic adenocarcinoma cell line LNCaP. Endocrinology 1996, 137:4468-4474.
37. Simons K, Ikonen E: Functional rafts in cell membranes. Nature 1997, 387:569-572.
38. Hager MH, Solomon KR, Freeman MR: The role of cholesterol in prostate cancer. Curr Opin Clin Nutr Metab Care 2006, 9:379-385.
39. Freeman MR, Cinar B, Lu ML: Membrane rafts as potential sites of nongenomic hormonal signaling in prostate cancer. Trends Endocrinol Metab 2005, 16:273-279.
40. Zhuang L, Lin J, Lu ML, et al.: Cholesterol-rich lipid rafts mediate akt-regulated survival in prostate cancer cells. Cancer Res 2002, 62:2227-2231.
41. Smith SM, Lei Y, Liu J, et al.: Luteinizing hormone receptors translocate to plasma membrane microdomains after binding of human chorionic gonadotropin. Endocrinology 2006, 147:1789-1795.
42. Lawrence JC, Saslowsky DE, Edwardson JM, Henderson RM: Real-time analysis of the effects of cholesterol on lipid raft behavior using atomic force microscopy. Biophys J 2003, 84:1827-1832.
43. El Sheikh SS, Domin J, Abel P, et al.: Phosphorylation of both EGFR and ErbB2 is a reliable predictor of prostate cancer cell proliferation in response to EGF. Neoplasia 2004, 6:846-853.
44. Horinaga M, Okita H, Nakashima J, et al.: Clinical and pathologic significance of activation of signal transducer and activator of transcription 3 in prostate cancer. Urology 2005, 66:671-675.
45. Zhuang L, Kim J, Adam RM, et al.: Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J Clin Invest 2005, 115:959-968. This paper solidified the foundation of basic science evidence in support of a cholesterol-mediated antineoplastic mechanism of action of statins in the setting of prostate cancer and furthered understanding of the role of lipid rafts in prostate cancer cell survival.
46. Dobs AS, Schrott H, Davidson MH, et al.: Effects of high-dose simvastatin on adrenal and gonadal steroidogenesis in men with hypercholesterolemia. Metabolism 2000, 49:1234-1238.
47. Smals AG, Weusten JJ, Benraad TJ, Kloppenborg PW: The HMG-CoA reductase inhibitor simvastatin suppresses human testicular testosterone synthesis in vitro by a selective inhibitory effect on 17-ketosteroid- oxidoreductase enzyme activity. J Steroid Biochem Mol Biol 1991, 38:465-468.
48. Segarra A, Chacon P, Vilardell M, Piera LL: Prospective case control study to determine the effect of lovastatin on serum testosterone and cortisol concentrations in hyperlipidemic nephrotic patients with chronic renal failure. Nephron 1996, 73:186-190.
49. Bernini GP, Argenio GF, Gasperi M, et al.: Effects of long-term simvastatin treatment on testicular and adrenal steroidogenesis in hypercholesterolemic patients. J Endocrinol Invest 1994, 17:227-233.
50. Bohm M, Herrmann W, Wassmann S, et al.: Does statin therapy influence steroid hormone synthesis? Z Kardiol 2004, 93:43-48.
51. Dobs AS, Miller S, Neri G, et al.: Effects of simvastatin and pravastatin on gonadal function in male hypercholesterolemic patients. Metabolism 2000, 49:115-121.
52. Hall SA, Page ST, Travison TG, et al.: Do statins affect androgen levels in men? Results from the Boston area community health survey. Cancer Epidemiol Biomarkers Prev 2007, 16:1587-1594. One hypothesized mechanism through which statins inhibit prostate cancer was that statins may reduce serum androgen levels. This large population-based cohort study was the first to demonstrate that statin use was not associated with changes in serum androgen levels.
53. Page ST, Lin DW, Mostaghel EA, et al.: Persistent intraprostatic androgen concentrations after medical castration in healthy men. J Clin Endocrinol Metab 2006, 91:3850-3856.
54. Pelletier G, Luu-The V, El-Alfy M, et al.: Immunoelectron microscopic localization of 3beta-hydroxysteroid dehydrogenase and type 5 17beta-hydroxysteroid dehydrogenase in the human prostate and mammary gland. J Mol Endocrinol 2001, 26:11-19.
55. Heemers H, Vanderhoydonc F, Roskams T, et al.: Androgens stimulate coordinated lipogenic gene expression in normal target tissues in vivo. Mol Cell Endocrinol 2003, 205:21-31.
56. Eberle D, Hegarty B, Bossard P, et al.: SREBP transcription factors: master regulators of lipid homeostasis. Biochimie 2004, 86:839-848.
57. Ettinger SL, Sobel R, Whitmore TG, et al.: Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independence. Cancer Res 2004, 64:2212-2221.
58. Graaf MR, Richel DJ, van Noorden CJ, Guchelaar HJ: Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. Cancer Treat Rev 2004, 30:609-641.
59. Weber MJ, Gioeli D: Ras signaling in prostate cancer progression. J Cell Biochem 2004, 91:13-25.
60. Lee SJ, Ha MJ, Lee J, et al.: Inhibition of the 3-hydroxy-3- methylglutaryl-coenzyme A reductase pathway induces p53-independent transcriptional regulation of p21(WAF1/CIP1) in human prostate carcinoma cells. J Biol Chem 1998, 273:10618-10623.
61. Moyad MA, Merrick GS, Butler WM, et al.: Statins, especially atorvastatin, may improve survival following brachytherapy for clinically localized prostate cancer. Urol Nurs 2006, 26:298-303.
62. Shippy AM, Katz MS, Yamada Y, et al.: Statin use and clinical outcomes after high dose radiotherapy for prostate cancer [abstract 203]. Int J Radiat Biol 2007, 69:S113.
63. Hong SK, Han BK, Jeong SJ, et al.: Effect of statin therapy on early return of potency after nerve sparing radical retropubic prostatectomy. J Urol 2007, 178:613-616.
64. American Cancer Society. Cancer Facts & Figures 2007. Atlanta, GA: American Cancer Society; 2007.
65. Cox J, Clark S, Colli JL: Exploring causes for declining prostate cancer mortality rates in the United States between 1993 and 2003 [abstract 203]. Proceedings of the American Urological Association Meeting. Anaheim, CA; May 19-24, 2007.